Biosimilars
Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versio...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_90326 | ||
| 005 | 20220727 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220727s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a intechopen.87638 | ||
| 020 | |a 9781838819439 | ||
| 020 | |a 9781838819354 | ||
| 020 | |a 9781839681677 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/intechopen.87638 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MMG |2 bicssc | |
| 100 | 1 | |a Feijó Azevedo, Valderilio |4 edt | |
| 700 | 1 | |a Moots, Robert |4 edt | |
| 700 | 1 | |a Feijó Azevedo, Valderilio |4 oth | |
| 700 | 1 | |a Moots, Robert |4 oth | |
| 245 | 1 | 0 | |a Biosimilars |
| 260 | |b IntechOpen |c 2022 | ||
| 300 | |a 1 electronic resource (106 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |4 https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a Pharmacology | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/9829/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/90326 |7 0 |z DOAB: description of the publication |